First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase
STOCKHOLM, June 10, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-powered skin health solutions, today announced that the first patient has been enrolled in a new study to assess flare prediction in Atopic Dermatitis. The primary objective of...
STOCKHOLM, June 10, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-powered skin health solutions, today announced that the first patient has been enrolled in a new study to assess flare prediction in Atopic Dermatitis. The primary objective of...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.